CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 90 enrolled
Drug / intervention
G3215 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02692040
NCT02692040Phase 1Completed
CompareCT.gov

A Randomised, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Gut Hormone Analogue G3215 in Adult Subjects

Imperial College London·interventional·Posted Feb 25, 2016·Updated Dec 23, 2020

In Brief

A Phase 1 clinical trial evaluating G3215 and Placebo for Diabetes Mellitus and Obesity. Completed, enrolled 90 participants across 1 site.

Detailed Summary

A randomised, placebo controlled Phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of G3215 in adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Obesity
CountriesUnited Kingdom
CollaboratorsMedical Research Council, Covance

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 25, 2016
Enrollment StartJan 1, 2015
Primary CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 10.4 years ago

Interventions

G3215drug

Gut hormone analogue

Placebodrug

0.9% saline